This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Harbour BioMed Wins Amgen Patent Suit
Business patent infringement lawsuit

Harbour BioMed Wins Amgen Patent Suit

Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026

Sentiment
50
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The verdict is a significant win for Harbour BioMed, potentially boosting its stock and market valuation due to the awarded damages and validation of its technology. Conversely, Amgen faces a financial penalty and potential reputational damage, which could negatively impact its stock price and investor confidence in its intellectual property practices.

Biotechnology Pharmaceuticals
Event Summary

Harbour BioMed secured a landmark victory in a patent infringement lawsuit against Amgen and its subsidiary Teneobio in the United States — United States District Court for the District of Delaware. The jury found that Amgen willfully infringed Harbour BioMed's Grosveld Patent, which protects its antibody discovery platform, and awarded $20.2 million in damages, with the potential to be trebled to $60.6 million. This outcome validates Harbour BioMed's proprietary transgenic rodent technology and its commitment to protecting scientific innovation, while also setting a precedent in the global antibody patent landscape. Harbour BioMed plans to continue enforcing its broader patent portfolio, including an appeal to the United States — United States Court of Appeals for the Third Circuit for another patent with even greater financial implications.

Entities Involved
priv
Harbour BioMed
Harbour BioMed secured a complete victory in its patent infringement lawsuit against Amgen and Teneobio, validating its proprietary transgenic rodent technology and entitling it to $20.2 million in damages, with potential for up to $60.6 million. This strengthens its position as an innovator in the antibody technology field.
Importance 100.0 Sentiment 70.0
stock
Amgen
Amgen, along with its subsidiary Teneobio, was found by a jury to have willfully infringed Harbour BioMed's patent, resulting in a $20.2 million damages award against them, with potential for trebling to $60.6 million. This verdict negatively impacts Amgen's reputation and financial standing.
Importance 90.0 Sentiment -50.0
priv
Teneobio
Teneobio, an Amgen subsidiary, was found to have infringed Harbour BioMed's patent, contributing to the damages awarded against Amgen. This event reflects negatively on Teneobio's intellectual property practices.
Importance 70.0 Sentiment -50.0
govactor
United States — United States District Court for the District of Delaware
The United States — United States District Court for the District of Delaware was the venue where the patent infringement lawsuit was heard, and its jury delivered the decisive verdict in favor of Harbour BioMed.
Importance 30.0 Sentiment 0.0
per
Frank Grosveld
Professor Frank Grosveld is the founder of Harbour Antibodies and the inventor of the Grosveld Patent, which was at the center of the patent infringement lawsuit. His invention's validity was reaffirmed by the jury's verdict.
Importance 20.0 Sentiment 20.0
govactor
United States — United States Court of Appeals for the Third Circuit
Importance 0 Sentiment 0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.